ID

12631

Descripción

An Observational Study of the Functional Capacity of Heart Failure; ODM derived from: https://clinicaltrials.gov/show/NCT02350114

Link

https://clinicaltrials.gov/show/NCT02350114

Palabras clave

  1. 7/12/15 7/12/15 -
Subido en

7 de diciembre de 2015

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Heart Failure NCT02350114

Eligibility Acute Heart Failure NCT02350114

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
have a left ventricular ejection fraction (lvef) 40 percent, as assessed by any method, e.g., echocardiography, a multigated acquisition (muga) scan or magnetic resonance imaging (mri);
Descripción

left ventricular ejection fraction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
present with signs and symptoms considered to be primarily due to ahf and be admitted to the hospital for ahf;
Descripción

hospitalization with signs and symptoms of ahf

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0264714
UMLS CUI [2]
C0019993
confirmation verbally that the patient was ambulatory, i.e., able to walk >30m, prior to developing symptoms of ahf leading to the current admission;
Descripción

Patient is ambulatory prior to admission

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3693818
be capable of understanding the nature of the trial; be willing and able to comply with the inpatient and outpatient study protocol requirements for the duration of the study; and be willing to participate, as documented by written informed consent.
Descripción

Informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
have a systolic blood pressure <90mmhg or >170mmhg at baseline;
Descripción

systolic blood pressure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0871470
have an anticipated need for an invasive procedure within 3 days of study enrollment, e.g., due to hemodynamic or cardiac rhythm instability, or acute coronary syndrome, requiring procedures including, but not limited to, cardiac catheterization, placement of a defibrillator/pacemaker, or placement of a pulmonary artery catheter;
Descripción

have an anticipated need for an invasive procedure within 3 days of study enrollment

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1548804
have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy (as defined by any wall thickness > 1.8cm) that is obstructive, or uncorrected severe valvular disease (except mitral regurgitation);
Descripción

have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy that is obstructive, or uncorrected severe valvular disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018801
UMLS CUI [2]
C0878544
UMLS CUI [3]
C3258293
have any other comorbidities that limit ambulation more than the patient's heart failure, e.g., symptomatic peripheral arterial disease, copd, arthritis or other condition, as confirmed verbally with the patient;
Descripción

have any other comorbidities that limit ambulation more than the patient's heart failure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0439801
UMLS CUI [3]
C0009488
have severe renal insufficiency (defined as a gfr <30ml/min/1.73m2 according to the mdrd equation);
Descripción

have severe renal insufficiency

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0035078
have an anticipated survival of less than 90 days, for any reason;
Descripción

have an anticipated survival of less than 90 days

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
have received an investigational agent (drug, device or biologic product) within 30 days (or, if longer, 5 half-lives for a drug or biologic agent) prior to study entry, or be planning to receive an investigational agent at any time throughout the full duration of the study until at least study day 35;
Descripción

study subject participation status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigators opinion, makes it inappropriate for the patient to participate in this clinical trial.
Descripción

have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial.

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2]
C0439801
UMLS CUI [3]
C0009488

Similar models

Eligibility Acute Heart Failure NCT02350114

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
left ventricular ejection fraction
Item
have a left ventricular ejection fraction (lvef) 40 percent, as assessed by any method, e.g., echocardiography, a multigated acquisition (muga) scan or magnetic resonance imaging (mri);
boolean
C0428772 (UMLS CUI [1])
hospitalization with signs and symptoms of ahf
Item
present with signs and symptoms considered to be primarily due to ahf and be admitted to the hospital for ahf;
boolean
C0264714 (UMLS CUI [1])
C0019993 (UMLS CUI [2])
Patient is ambulatory prior to admission
Item
confirmation verbally that the patient was ambulatory, i.e., able to walk >30m, prior to developing symptoms of ahf leading to the current admission;
boolean
C3693818 (UMLS CUI [1])
Informed consent
Item
be capable of understanding the nature of the trial; be willing and able to comply with the inpatient and outpatient study protocol requirements for the duration of the study; and be willing to participate, as documented by written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
systolic blood pressure
Item
have a systolic blood pressure <90mmhg or >170mmhg at baseline;
boolean
C0871470 (UMLS CUI [1])
have an anticipated need for an invasive procedure within 3 days of study enrollment
Item
have an anticipated need for an invasive procedure within 3 days of study enrollment, e.g., due to hemodynamic or cardiac rhythm instability, or acute coronary syndrome, requiring procedures including, but not limited to, cardiac catheterization, placement of a defibrillator/pacemaker, or placement of a pulmonary artery catheter;
boolean
C1548804 (UMLS CUI [1])
have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy that is obstructive, or uncorrected severe valvular disease
Item
have a primary hf etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic cardiomyopathy (as defined by any wall thickness > 1.8cm) that is obstructive, or uncorrected severe valvular disease (except mitral regurgitation);
boolean
C0018801 (UMLS CUI [1])
C0878544 (UMLS CUI [2])
C3258293 (UMLS CUI [3])
have any other comorbidities that limit ambulation more than the patient's heart failure
Item
have any other comorbidities that limit ambulation more than the patient's heart failure, e.g., symptomatic peripheral arterial disease, copd, arthritis or other condition, as confirmed verbally with the patient;
boolean
C0525058 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])
have severe renal insufficiency
Item
have severe renal insufficiency (defined as a gfr <30ml/min/1.73m2 according to the mdrd equation);
boolean
C0035078 (UMLS CUI [1])
have an anticipated survival of less than 90 days
Item
have an anticipated survival of less than 90 days, for any reason;
boolean
C0023671 (UMLS CUI [1])
study subject participation status
Item
have received an investigational agent (drug, device or biologic product) within 30 days (or, if longer, 5 half-lives for a drug or biologic agent) prior to study entry, or be planning to receive an investigational agent at any time throughout the full duration of the study until at least study day 35;
boolean
C2348568 (UMLS CUI [1])
have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigator's opinion, makes it inappropriate for the patient to participate in this clinical trial.
Item
have any other clinically significant laboratory abnormality, medical condition or social circumstance that, in the investigators opinion, makes it inappropriate for the patient to participate in this clinical trial.
boolean
C0525058 (UMLS CUI [1])
C0439801 (UMLS CUI [2])
C0009488 (UMLS CUI [3])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial